ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

ClinicalTrials.gov ID: NCT00345683

Public ClinicalTrials.gov record NCT00345683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.

Study identification

NCT ID
NCT00345683
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
4,021 participants

Conditions and interventions

Interventions

  • GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014) Biological
  • M-M-R II Biological
  • PedvaxHIB Biological
  • Prevnar Biological
  • Varivax Biological

Biological

Eligibility (public fields only)

Age range
12 Months to 15 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2007
Primary completion
Aug 31, 2008
Completion
Oct 31, 2008
Last update posted
Nov 28, 2016

2007 – 2008

United States locations

U.S. sites
55
U.S. states
21
U.S. cities
48
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205
GSK Investigational Site Birmingham Alabama 35244
GSK Investigational Site Benton Arkansas 72015
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Fresno California 93710
GSK Investigational Site Fresno California 93726
GSK Investigational Site Madera California 93637
GSK Investigational Site Slinas California 93901
GSK Investigational Site West Covina California 91790
GSK Investigational Site Boulder Colorado 80303
GSK Investigational Site Longmont Colorado 80501
GSK Investigational Site Plantation Florida 33324
GSK Investigational Site Nampa Idaho 208 463 3126
GSK Investigational Site Waukee Iowa 50263
GSK Investigational Site West Desmoines Iowa 50266
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Lexington Kentucky 40503
GSK Investigational Site Bossier City Louisiana 71111
GSK Investigational Site Boston Massachusetts 02130
GSK Investigational Site Nies Michigan 49120
GSK Investigational Site Portage Michigan 49024
GSK Investigational Site Stevensville Michigan 49127
GSK Investigational Site Saint Paul Minnesota 55108
GSK Investigational Site Las Vegas Nevada 89104
GSK Investigational Site Ithaca New York 14850
GSK Investigational Site New Hartford New York 13413
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Boardman Ohio 44512
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Cleveland Ohio 44121
GSK Investigational Site North Canton Ohio 44720
GSK Investigational Site South Euclid Ohio 44121
GSK Investigational Site Erie Pennsylvania 16505
GSK Investigational Site Greenville Pennsylvania 16125
GSK Investigational Site Pittsburgh Pennsylvania 15217
GSK Investigational Site Pittsburgh Pennsylvania 15220
GSK Investigational Site Pittsburgh Pennsylvania 15227
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Pittsburgh Pennsylvania 15241
GSK Investigational Site Wexford Pennsylvania 15090
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Kingsport Tennessee 37660
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Ogden Utah 84405
GSK Investigational Site Orem Utah 84057
GSK Investigational Site Pleasant Gorve Utah 84062
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site South Jordan Utah 84095
GSK Investigational Site West Jordan Utah 84088
GSK Investigational Site Madison Wisconsin 53792
GSK Investigational Site Marshfield Wisconsin 54449

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00345683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 28, 2016 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00345683 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →